Sangamo Therapeutics Inc SGMO.OQ SGMO.O is expected to show a rise in quarterly revenue when it reports results on March 16 (estimated) for the period ending December 31 2025
The Richmond California California-based company is expected to report a 168.8% increase in revenue to $20.3 million from $7.55 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Sangamo Therapeutics Inc is for a loss of 6 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 404.9% above its last closing price of $0.40
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | 0.03 | 0.00 | -0.11 | Missed | -64,805.9 |
Jun. 30 2025 | -0.13 | -0.13 | -0.08 | Beat | 37.3 |
Mar. 31 2025 | -0.13 | -0.13 | -0.14 | Missed | -7.1 |
Dec. 31 2024 | -0.08 | -0.09 | -0.11 | Missed | -20.5 |
Sep. 30 2024 | -0.06 | -0.03 | 0.04 | Beat | 240 |
Jun. 30 2024 | -0.15 | -0.15 | -0.18 | Missed | -23.5 |
Mar. 31 2024 | -0.22 | -0.21 | -0.27 | Missed | -26.3 |
Dec. 31 2023 | -0.26 | -0.34 | Missed | -32.7 |
This summary was machine generated March 13 at 20:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)